Parkman Healthcare Partners LLC Purchases 9,558 Shares of Entera Bio Ltd. (NASDAQ:ENTX)

Parkman Healthcare Partners LLC boosted its position in Entera Bio Ltd. (NASDAQ:ENTX) by 2.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 411,076 shares of the company’s stock after purchasing an additional 9,558 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 1.15% of Entera Bio worth $781,000 at the end of the most recent quarter.

Separately, Signature Estate & Investment Advisors LLC purchased a new position in Entera Bio during the 3rd quarter valued at about $90,000. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Entera Bio Price Performance

Shares of NASDAQ:ENTX opened at $1.60 on Wednesday. The business has a fifty day moving average price of $1.77 and a 200-day moving average price of $1.85. The company has a market capitalization of $57.25 million, a PE ratio of -6.15 and a beta of 1.55. Entera Bio Ltd. has a 1-year low of $0.52 and a 1-year high of $3.35.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Entera Bio in a research note on Monday, November 11th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.